The Approval Granted By The Us Food And Drug Administration (Usfda) Is To Market Triazolam Tablets Of Strengths 0.125 Mg And 0.25 Mg, The Company Said In A Regulatory Filing.Zydus Lifesciences Ltd On Friday Said It Has Received Final Approval From The Us Health Regulator To Market Its Generic Version Of Triazolam Tablets Used On A Short-Term Basis To Treat Insomnia. The Approval Granted By The Us Food And Drug Administration (Usfda) Is To Market Triazolam Tablets Of Strengths 0.125 Mg And 0.25 Mg, The Company Said In A Regulatory Filing. The Medicine Is Used On A Short-Term Basis To Treat Insomnia And Difficulty Falling Asleep Or Staying Asleep. It Works By Slowing Activity In The Brain To Allow Sleep. It Will Be Manufactured At The Group'S Formulation Manufacturing Facility At Moraiya.
